

# Journal of Visualized Experiments

## Mesenchymal Stem Cell Isolation from Pulp Tissue and Co-Culture with Cancer Cells to Study Their Interactions

--Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE58825R2
<b>Full Title:</b>	Mesenchymal Stem Cell Isolation from Pulp Tissue and Co-Culture with Cancer Cells to Study Their Interactions
<b>Keywords:</b>	DPSCs; stem cells; MSCs; Prostate cancer; PC3-; co-culture; metastasis; Migration
<b>Corresponding Author:</b>	Selami Demirci National Institutes of Health Clinical Center Bethesda, UNITED STATES
<b>Corresponding Author's Institution:</b>	National Institutes of Health Clinical Center
<b>Corresponding Author E-Mail:</b>	selami.demirci@nih.gov
<b>Order of Authors:</b>	Ayşegül Doğan Selami Demirci Hüseyin Apdik Ezgi Aşşar Apdik Fikrettin Şahin
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Istanbul/Turkey



**TITLE:**

Mesenchymal Stem Cell Isolation from Pulp Tissue and Co-Culture with Cancer Cells to Study Their Interactions

**AUTHORS AND AFFILIATIONS:**

Ayşegül Doğan<sup>1</sup>, Selami Demirci<sup>2</sup>, Hüseyin Apdik<sup>1</sup>, Ezgi Avşar Apdik<sup>1</sup>, Fikrettin Şahin<sup>1</sup>

<sup>1</sup>Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey

<sup>2</sup>National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Sickle Cell Branch, Bethesda, MA, USA

**Corresponding Author:**

Selami Demirci (selami.demirci@nih.gov)

**Email Addresses of Co-authors:**

Ayşegül Doğan (aysegul.dogan@yeditepe.edu.tr)

Hüseyin Apdik (huseyin.abdik@yeditepe.edu.tr)

Ezgi Avşar Apdik (ezgi.avsar@yeditepe.edu.tr)

Fikrettin Şahin (fsahin@yeditepe.edu.tr)

**KEYWORDS:**

Co-culture, trans-well, condition medium, mesenchymal stem cell, prostate cancer cell, cell migration, dental stem cell

**SUMMARY:**

We provide protocols for evaluation of mesenchymal stem cells isolated from dental pulp and prostate cancer cell interactions based on direct and indirect co-culture methods. Condition medium and trans-well membranes are suitable to analyze indirect paracrine activity. Seeding differentially stained cells together is an appropriate model for direct cell-cell interaction.

**ABSTRACT:**

Cancer as a multistep process and complicated disease is not only regulated by individual cell proliferation and growth but also controlled by tumor environment and cell-cell interactions. Identification of cancer and stem cell interactions, including changes in extracellular environment, physical interactions, and secreted factors, might enable the discovery of new therapy options. We combine known co-culture techniques to create a model system for mesenchymal stem cells (MSCs) and cancer cell interactions. In the current study, dental pulp stem cells (DPSCs) and PC-3 prostate cancer cell interactions were examined by direct and indirect co-culture techniques. Condition medium (CM) obtained from DPSCs and 0.4 µm pore sized trans-well membranes were used to study paracrine activity. Co-culture of different cell types together was performed to study direct cell-cell interaction. The results revealed that CM increased cell proliferation and decreased apoptosis in prostate cancer cell cultures. Both CM and trans-well system increased cell migration capacity of PC-3 cells. Cells stained with different membrane dyes were seeded into the same culture vessels, and DPSCs participated in a self-

organized structure with PC-3 cells under this direct co-culture condition. Overall, the results indicated that co-culture techniques could be useful for cancer and MSC interactions as a model system.

## **INTRODUCTION:**

Mesenchymal stem cells (MSCs), with the ability of differentiation and contribution to regeneration of mesenchymal tissues such as bone, cartilage, muscle, ligament, tendon, and adipose, have been isolated from almost all tissues in the adult body<sup>1,2</sup>. Other than providing tissue homeostasis by producing resident cells in case of chronic inflammation or an injury, they produce vital cytokines and growth factors to orchestrate angiogenesis, immune system, and tissue remodeling<sup>3</sup>. The interaction of MSCs with cancer tissue is not well-understood, but accumulating evidence suggests that MSCs might promote tumor initiation, progression, and metastasis<sup>4</sup>.

The homing ability of MSCs to the injured or chronically inflamed area makes them a valuable candidate for stem cell-based therapies. However, cancer tissues, “never healing wounds”, also release inflammatory cytokines, pro-angiogenic molecules, and vital growth factors, which attract MSCs to the cancerogenous area<sup>5</sup>. While there are limited reports showing inhibitory effects of MSCs on cancer growth<sup>6,7</sup>, their cancer progression and metastasis promoting effects have been extensively reported<sup>8</sup>. MSCs directly or indirectly affect carcinogenesis in different ways including suppressing immune cells, secreting growth factors/cytokines that support cancer cell proliferation and migration, enhancing angiogenic activity, and regulating epithelial-mesenchymal transition (EMT)<sup>9,10</sup>. Tumor environment consists of several cell types including cancer-associated fibroblasts (CAFs) and/or myofibroblasts, endothelial cells, adipocytes, and immune cells<sup>11</sup>. Of those, CAFs are the most abundant cell type in the tumor area that secrete various chemokines promoting cancer growth and metastasis<sup>8</sup>. It has been shown that bone marrow-derived MSCs can differentiate into CAFs in the tumor stroma<sup>12</sup>.

Dental pulp stem cells (DPSCs), characterized as the first dental tissue-derived MSCs by Gronthos *et al.*<sup>13</sup> in 2000 and then widely investigated by others<sup>14,15</sup>, express pluripotency markers such as *Oct4*, *Sox2*, and *Nanog*<sup>16</sup> and can differentiate into various cell lineages<sup>17</sup>. Gene and protein expression analysis proved that DPSCs produce comparable levels of growth factors/cytokines with other MSCs such as vascular endothelial growth factor (VEGF), angiogenin, fibroblast growth factor 2 (FGF2), interleukin-4 (IL-4), IL-6, IL-10, and stem cell factor (SCF), as well as fms-like tyrosine kinase-3 ligand (Flt-3L) that might promote angiogenesis, modulate immune cells, and support cancer cell proliferation and migration<sup>18-20</sup>. While the interactions of MSCs with cancer environment have been well-documented in the literature, the relationship between DPSCs and cancer cells has not been evaluated yet. In the present study, we established co-culture and condition medium treatment strategies for a highly metastatic prostate cancer cell line, PC-3, and DPSCs to propose potential action of mechanism of dental MSCs in cancer progression and metastasis.

## **PROTOCOL:**

Written informed consent of the patients was obtained after the approval from the Institutional Ethics Committee.

## **1. DPSC Isolation and Culture**

1.1. Transfer wisdom teeth obtained from young adults aged between 17 and 20 to 15 mL tubes containing complete Dulbecco's Modified Eagle Medium (DMEM) [low glucose DMEM media, supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin/amphotericin (PSA) solution], within 8 h after resection. Keep the tissue material cold (4 °C) during transfer to avoid potential cell death.

1.2. Remove the pulp tissue by sterile extraction forceps from the center of the tooth carefully, place the pulp tissue in the cold complete DMEM medium in 10 cm tissue culture dishes, and mince them into small pieces (2-3 mm) by scalpel.

Note: All experimental procedures should be carried out under sterile conditions in laminar flow hood. This non-enzymatic technique has been previously used<sup>21-23</sup>.

1.3. Place small pulp tissues inside the tissue culture treated 6-well plates and add 200 µL of complete DMEM media to cover each small pulp tissue pieces.

1.4. Incubate the tissue culture wells at 37 °C in a humidified air atmosphere (80% humidity) with 5% CO<sub>2</sub> for 2 h to provide tissue attachment.

Note: This step could be prolonged to 3-4 h by controlling the evaporation of media.

1.5. Add appropriate volume (2-2.5 mL) of complete DMEM medium to the wells and incubate at 37 °C in a humidified air atmosphere with 5% CO<sub>2</sub> for cells to spread from the tissue.

Note: Cells become visible after approximately 4 days and reach confluency after 8-9 days.

1.6. When cells reach 80% confluency, remove media from 6-well plates, wash with 2 mL of phosphate buffered saline (PBS), and add 2 mL of trypsin. Incubate for 2 min in an incubator at 37 °C with humidified air atmosphere and 5% CO<sub>2</sub>. Then add 2 mL of complete DMEM medium followed by 2 min incubation to inhibit trypsin. Centrifuge cells at 300 x g for 5 min to pellet cells.

1.7. Passage cells to the flasks in complete DMEM media and store for further experiments. Add 15 mL of complete DMEM media to the T-75 flasks and transfer cells from two wells of the 6-well plate to one T-75 flasks and incubate at 37 °C with humidified air atmosphere and 5% CO<sub>2</sub>.

## **2. Characterization of DPSCs**

2.1. Perform morphological analyses.

2.1.1. Seed cells (step 1.6) in tissue culture coated flasks (or 6-well plates) in complete DMEM medium for at least 8 passages to observe cell morphology.

2.1.2. Visualize cells by light microscope and define fibroblast-like cell morphology. Cells should attach to the culture dishes and have spindle-like cell morphology.

Note: Alternatively, cells can be cultured as single cells for up to 14 days in well-plates to observe colony formation capacity that is a specific characteristic of fibroblasts and MSCs.

## 2.2. Perform surface marker analyses.

2.2.1. Trypsinize the cells from step 1.7. Remove media from the T-75 tissue culture flask, wash with 2 mL of PBS, and add 2 mL of trypsin. Incubate for 2 min in an incubator at 37 °C with humidified air atmosphere and 5% CO<sub>2</sub>. Then add 2 mL of complete DMEM medium followed by 2 min incubation to inhibit trypsin. Centrifuge cells at 300 x g for 5 min to pellet cells.

2.2.2. Fix the cells with 4% paraformaldehyde for 20 min at room temperature in 1.5 mL tubes and then wash them with 500 µL of PBS 3 times to remove paraformaldehyde.

2.2.3. Incubate fixed cells with the antibodies against CD29, CD34, CD14, CD45, CD90, CD105, CD166, and CD73 for 1 h at 4 °C in 100 µL of PBS.

Note: The concentration of antibody used is 0.5 µg/mL. CD34, CD14, and CD45 are used as negative markers, while CD29, CD90, CD105, CD166, and CD73 are used as positive cell surface markers for MSCs.

2.2.4. Wash cells 3 times with PBS and use respective secondary antibodies such as fluorescein isothiocyanate (FITC), phycoerythrin (PE), etc. for labelling. Incubate cells with 1:500 diluted secondary antibodies in 100 µL of PBS for 30 min at 4 °C and wash 3 times with PBS.

2.2.5. Keep samples in the dark for flow cytometry analysis and detect positive and negative staining by flow cytometry.

Note: Use unstained control cells to arrange forward and side scatter. Arrange gating of positively stained populations by excluding dead cells, debris, and un-stained population. Use 100 µm nozzle with 45 psi sheath pressure and collect 10,000 events to determine positive DPSCs by arranging channels.

## 2.3. Perform differentiation of DPSCs.

2.3.1. Seed  $1 \times 10^4$  cells onto 24-well plates in complete DMEM media and incubate for 24 h at 37 °C in a humidified air atmosphere with 5% CO<sub>2</sub>.

2.3.2. Formulate differentiation media using complete DMEM medium as base media. Prepare osteogenic media by mixing 100 nM dexamethasone, 10 mM  $\beta$ -glycerophosphate, and 0.2 mM ascorbic acid. Prepare chondrogenic media by mixing 1 $\times$  insulin-transferrin-selenium (ITS-G), 100 nM dexamethasone, 100 ng/mL transforming growth factor beta (TGF- $\beta$ ), 14  $\mu$ g/mL ascorbic acid, and 1 mg/mL bovine serum albumin (BSA). Prepare adipogenic media by mixing 100 nM dexamethasone, 5  $\mu$ g/mL insulin, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), and 60  $\mu$ M indomethacin.

Note: Differentiation media can be kept at 4 °C for at least one week.

2.3.3. Change growth media to osteo-, chondro-, or adipo-genic differentiation media and refresh media twice a week for two weeks.

2.3.4. Confirm differentiation by von Kossa and Alcian blue staining, enzyme activity (alkaline phosphatase activity), immunocytochemistry, and quantitative polymerase chain reaction (qPCR) analyses according to the protocols previously described<sup>21</sup>.

2.3.4.1. Perform von Kossa and Alcian blue stainings on cells that are fixed with 4% paraformaldehyde at room temperature for 10 min. Wash the fixed cells with PBS and stain them with the vonKossa kit according to the manufacturer's recommendations to observe calcium deposits.

2.3.4.2. Prepare the Alcian blue staining solution by dissolving 1.00 g of Alcian blue dye in 100 mL of 3% (v/v) acetic acid for further staining. Wash the fixed cells with PBS and stain cells for 30 min with Alcian blue solution. Visualize the stained samples by a light microscope.

### 3. Preparation of Condition Medium (CM)

3.1. Replace media of cells from step 1.7 with fresh complete DMEM 24 h before CM collection.

Note: Passage 2-4 is recommended.

3.2. Collect condition medium (CM) from cultured DPSCs when cells reach 80% confluency. Centrifuge collected media at 300  $\times$  g for 5 min to remove waste tissue material and cell debris.

Note: Alternatively, use 0.2  $\mu$ m syringe filters to remove debris from the condition medium.

3.3. Collect supernatant and store at -20 °C for further experiments.

Note: Keep the supernatant at -80 °C for long-term storage.

### 4. Treatment of Cancer Cells with CM

4.1. Perform cell viability analyses.

4.1.1. Seed PC-3 cells (human prostate cancer cells) onto 96-well plates at a cell density of  $5 \times 10^3$  cells/well in complete DMEM and incubate in a humidified chamber at 37 °C and 5% CO<sub>2</sub> for 24 h.

4.1.2. Treat cells with 10, 20, 30, 40, and 50% of CM (v/v) mixed with complete DMEM for 24 h.

4.1.3. Measure cell viability by using 3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfo-phenyl)-2H-tetrazolium (MTS)-assay as described previously<sup>24</sup>.

4.2. Perform terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analyses.

4.2.1. Seed PC-3 cells onto 6-well cell culture plates at a cell density of  $2 \times 10^5$  cells/well and incubate in a humidified chamber at 37 °C and 5% CO<sub>2</sub> overnight.

4.2.2. Mix 20% CM (v/v) with complete DMEM medium and apply to the cells for 24 h.

4.2.3. Trypsinize cells and suspend in 50 µL of TUNEL reaction mixture (labeling solution + enzyme solution, supplied with the kit) and incubate at 37 °C for 60 min in a humidified and 5% CO<sub>2</sub> atmosphere.

Note: For trypsinization, remove media from 6-well cell culture plates, wash with 1 mL of PBS and add 500 µL of trypsin. Incubate for 2 min in an incubator at 37 °C with humidified air atmosphere and 5% CO<sub>2</sub>. Add 1 mL of complete DMEM medium followed by 2 min incubation to inhibit trypsin. Centrifuge cells at 300 x g for 5 min to pellet cells.

4.2.4. Rinse with PBS and analyze cells in PBS by using flow cytometry.

4.3. Perform qPCR analyses.

4.3.1. Seed PC-3 cells onto 6-well cell culture plates at a cell density of  $2 \times 10^5$  cells/well and incubate in a humidified incubator at 37 °C and 5% CO<sub>2</sub> overnight.

4.3.2. Mix 20% CM (v/v) with complete DMEM medium and apply to the cells for 24 h.

4.3.3. Trypsinize cells and collect cell pellet for RNA isolation and cDNA synthesis.

Note: Remove media from 6-well cell culture plates, wash with 1 mL of PBS, and add 500 µL of trypsin. Incubate 2 min in an incubator at 37 °C with humidified air atmosphere and 5% CO<sub>2</sub>. Add 1 mL of complete DMEM medium followed by 2 min incubation to inhibit trypsin. Centrifuge cells at 300 x g for 5 min to pellet cells.

4.3.4. Perform qPCR experiments according to the previously described protocol<sup>25</sup>.



#### 4.4. Perform cell migration of cancer cells.

4.4.1. Seed  $1 \times 10^5$  PC-3 cells onto 12-well plates and incubate in a humidified incubator overnight at 37 °C and 5% CO<sub>2</sub>.

4.4.2. Scratch cells with a sterile 200 µL tip and change medium immediately with fresh medium containing various concentrations of CM [e.g., 10, 20, 30, 40, and 50% of CM (v/v) mixed with complete DMEM].

4.4.3. Observe scratches under an inverted microscope and take pictures at different time intervals (0 and 24 h).

4.4.4. Measure the scratch closure by using Image J software using the formula:

$$\text{Scratch Closure (\%)} = \frac{\text{Scratch area (0 h)} - \text{Scratch area (24 h)}}{\text{Scratch area (0 h)}} \times 100$$

Note: Open the scratch image with Image J software. Draw a line that has the same magnitude as the scale bar that already exists in the image. Click analyze, set scale, and observe distance in pixels as the magnification of the drawn line. Write the size of the scale bar to the known distance part, arrange unit (pixels, cm, etc.), and click ok. Go to the analyze section again and click on measurements. This will first give the size of the scale bar as the selected unit. Click on one edge of scratch and drag until reaching the other end of the scratch. Note the value for each time point (0 h and 24 h). Plug these values into the formula above and calculate the scratch closure.

### 5. Cell Migration by Indirect Contact of Cancer Cells and DPSCs

5.1. Seed  $3 \times 10^4$  DPSCs onto 24-well plate inserts with 0.4 µm pore and incubate in a humidified incubator overnight at 37 °C.

5.2. Seed PC-3 cells onto 24-well plates at a cell density of  $5 \times 10^4$  and incubate in a humidified incubator overnight at 37 °C and 5% CO<sub>2</sub>.

5.3. Scratch PC-3 cells with a sterile 200 µL tip, change medium with fresh medium, and place inserts carrying DPSCs onto PC-3 cells.

5.4. Observe cells under an inverted microscope and take pictures at different time intervals (0 and 24 h) to analyze cell migration.

### 6. Co-culture Assay and Flow Cytometry Analysis

6.1. Label PC-3 cells and DPSCs by using PKH67 (green) and PKH26 (red) fluorescent cell linker dyes, respectively<sup>26</sup>.

6.2. Trypsinize PC-3 and DPSCs cells, respectively. Remove media from T-75 tissue culture flask, wash with 2 mL of PBS, and add 2 mL of trypsin. Incubate for 2 min in an incubator at 37 °C with humidified air atmosphere and 5% CO<sub>2</sub>. Add 2 mL of complete DMEM medium followed by 2 min incubation to inhibit trypsin.

6.3. Centrifuge cells at 300 x g for 5 min, discard supernatant, and resuspend cell pellets in the dye solution prepared in diluent-C buffer supplied by the kit (see **Table of Materials**).

6.4. Incubate cells in the dye solution for 10 min and terminate the staining reaction by adding 100 µL of FBS. Centrifuge cells at 300 x g for 5 min, discard the supernatant, and wash the cells with complete growth medium before co-culturing.

6.5. Plate labeled cells ( $5 \times 10^4$ /well) onto 6-well plates at 1:1 ratio (DPSCs:PC3). Maintain co-cultured cells in complete DMEM.

6.6. Collect cells after 24 h or 48 h incubation periods by centrifugation of cells at 300 x g for 5 min and washing with PBS.

6.7. Resuspend cells in 300 µL of fluorescence-activated cell sorting (FACS) buffer in 5 mL round bottom flow cytometry tubes. Vortex to disperse cell aggregates right before the sample analysis.

6.8. Use a 100 µm nozzle with 45 psi sheath pressure.

Note: Extremely high flow rate might decrease the sensitivity of fluorescence detection.

6.9. Use unstained control cells and single colored cells to adjust appropriate forward and side scatter laser voltage for cell types and compensation as mentioned previously<sup>27</sup>.

Note: Use gating for live cells to exclude cell debris, dead cells, or aggregates.

6.10. Collect 10,000 events (100,000 is preferable) to determine percent positive green DPSCs and red PC-3 cells by arranging FL-1 (green) and FL-2 (red) channels.

## REPRESENTATIVE RESULTS:

**Figure 1** depicts the general MSC characteristics of DPSCs under culture conditions. DPSCs exert fibroblast-like cell morphology after plating (**Figure 1B**). MSC surface antigens (CD29, CD73, CD90, CD105, and CD166) are highly expressed while hematopoietic markers (CD34, CD45, and CD14) are negative (**Figure 1C**). Changes at the morphological and molecular level related to osteo-, chondro-, and adipo-genic differentiation are observed in DPSCs culture followed by differentiation cocktail application (**Figure 1D**).

To determine the activity of secreted molecules from DPSCs on prostate cancer cell proliferation and migration, we applied CM that is collected from cultured dental stem cells and analyzed cancer cell proliferation and migratory behavior. CM treatment (20% v/v) was selected based on

MTS cell viability analyses. PC-3 cells treated with stem cell CM were subjected to the TUNEL assay and qPCR analyses to determine cell death and apoptotic regulation under control and experimental conditions. We concluded that CM treatment increased cell viability and reduced cell death in PC-3 cell culture. *Ex vivo* cell migration assay (scratch assay) was performed to evaluate whether CM of DPSCs affects PC-3 cancer cell migration. Treatment with the concentrations of 10% and 20% CM (v/v) increased scratch closure significantly in comparison to the control group at 24 h (**Figure 2**). Similarly, 20% CM (v/v) treatment induced upregulation of extracellular matrix protein gene expressions such as collagen I, fibronectin, and laminin, which play significant roles in cell migration.

We used two different culture techniques to establish direct and indirect co-cultures of PC-3 cells and DPSCs under *ex vivo* conditions. Trans-well system was selected to create an indirect interaction environment for PC-3 cancer cells. PC-3 cells were seeded onto the bottom of the well plate and inserts carrying DPSCs were placed on the top. Because we aimed to generate an in-direct interaction, trans-well membranes with 0.4  $\mu\text{m}$  pore size were used to prevent physical cell movement of DPSCs from the upper part to bottom part through the membrane. Secreted molecules from DPSCs increased scratch closure of PC-3 cells significantly compared to control cells. PC-3 cells co-cultured with DPSCs demonstrated a 51% scratch closure while control cells had a 38% closure after 24 h (**Figure 3A**). Direct co-cultures containing 1:1 ratio of DPSCs and PC-3 cells were used to analyze self-organization of stem cells and cancer cells. Cells were stained with red and green membrane dyes to distinguish different cell types under microscope. PC-3 cells stained with red fluorescence dye were surrounded by DPSCs in a tube-like structure after a 24 h incubation period. Co-cultured cells stained with fluorescent dyes were analyzed by flow cytometry based on fluorescence staining, and cell ratios were detected. DPSCs and PC-3 cells created a well-organized structure in which PC-3 cells proliferated rapidly after 48 h (**Figure 3B**). Although cells were seeded at an equal ratio (1:1) for direct co-culture, 62.22% of PC-3 cells were determined after 48 h incubation, indicating the higher proliferation rate of PC-3 cells.

#### FIGURE LEGENDS:

**Figure 1: Characterization of dental pulp stem cells (DPSCs).** (A) Pulp tissue obtained from the center of tooth. (B) Fibroblast-like cell morphology of DPSCs. Scale bar: 100  $\mu\text{m}$ . (C) Flow cytometry analyses of DPSCs. CD29, CD73, CD90, CD105, and CD 166 are positive surface markers, while CD14, CD34, and CD45 are negative surface markers. NC: negative control (growth medium treated cells). (D) Differentiation of DPSCs to mesenchymal cell types was confirmed with von Kossa staining, Alcian Blue staining, and lipid droplets (scale bar: 200  $\mu\text{m}$ ). Osteocalcin, collagen type II (Col II), and fatty acid binding protein 4 (FABP4) immunostainings showed the osteo-, chondro-, and adipogenic differentiation of DPSCs. Scale bar: 200  $\mu\text{m}$ . This figure is adapted from Dogan *et al.*<sup>34</sup>.

**Figure 2: Collection of condition medium (CM) from DPSCs for cell viability and scratch analyses.** TUNEL positive cells were decreased by 20% CM (v/v) application. Quantitative measurement of scratch closure showed that CM increased PC-3 cell migration. CM: conditioned medium; NC: negative control (growth medium treated cells). \*P < 0.05. This figure is adapted from Dogan *et al.*<sup>34</sup>.

**Figure 3. Methodology for trans-well cell migration assay and co-culture.** (A) PC-3 cell scratch closure in the trans-well co-culture system. (B) Interaction pattern of stained DPSCs (green fluorescence) and PC-3 cells (red fluorescence) after 24 h and 48 h of co-culture (1:1 seeding ratio). Higher PC-3 cell number was detected with respect to DPSCs. Scale bar: 200  $\mu$ m. This figure is adapted from Dogan *et al.*<sup>34</sup>.

## DISCUSSION:

Contribution of MSCs to tumor environment is regulated by several interactions including hybrid cell generation *via* cell fusions, entosis or cytokine and chemokine activities between stem cells and cancer cells<sup>28</sup>. Structural organization, cell-cell interactions, and secreted factors determine cancer cell behavior in terms of tumor promotion, progression, and metastasis to surrounding tissue. Proper *ex vivo* model systems to investigate the mechanisms behind the interactions of resident cell populations are required to understand cellular communications for cancer progression and metastasis.

We used DPSCs to create a model system for prostate cancer and dental stem cell interactions. The advantage of this type of adult stem cell is the accessibility of tissue source and easy isolation steps. On the other hand, using only DPSCs without comparison with well-known adult stem cell types is a limitation of this protocol. Current co-culture methods are categorized into direct and indirect techniques which include paracrine signaling of soluble secreted molecules and direct culture of different cell populations in the same environment<sup>29-31</sup>. CM of fully characterized DPSCs was used to evaluate paracrine signaling mediated cancer cell growth in culture. CM application is the simplest method for cell interaction studies and allows for observation of soluble mediator activities in the culture system. Although CM is not a fully adequate model system, CM application as a co-culture method is very efficient to observe cell-cell interactions *ex vivo*. CM of DPSCs increased the cell proliferation and migration of prostate cancer cells, indicating the acquisition of metastatic phenotype due to the factors secreted from DPSCs.

Another model of cell-cell interaction is the establishment of a physical barrier such as a trans-well membrane between cell populations<sup>30</sup>. Trans-well systems are divided into two types: those which allow cell movement through the pores, and those enabling transfer of secreted factors while hindering cell contact through the membrane as well. We used trans-wells with 0.4  $\mu$ m pore size to analyze the closure of PC-3 scratches, revealing higher cancer cell migration rate in the DPSC group compared to the control cells.

Although CM and trans-well based systems are advantageous for simply analyzing contributions of a particular cell type<sup>32</sup>, direct culturing of different subpopulations in the same environment is necessary in parallel with indirect co-culture methods. Seeding ratio can be controlled and structural organization of distinct populations can be easily analyzed by direct co-culture of MSC with cancer cells. We used 1:1 ratio of DPSCs and PC-3 cells stained with green and red fluorescence membrane dyes, respectively. DPSCs encircled PC-3 cells and created a tube-like structure in culture wells. PC-3 cells formed clusters in the form of islets surrounded by channel-like structures generated by DPSCs.

Recently, Brunetti *et al.* showed that DPSCs secrete TNF- related apoptosis- inducing ligand (TRAIL) during osteogenic differentiation and affect myeloma cancer cell viability, indicating the possible interactions of dental stem cells with cancer cells<sup>33</sup>. Our study is the first report that evaluates interactions of dental derived MSCs and prostate cancer cells as an *ex vivo* model. We used three different direct/indirect approaches in our experiments. Proliferation of cancer cells and high migration rates were detected either by CM and trans-well assays or by co-culturing differentially stained cells that allows for multiple interactions.

#### ACKNOWLEDGEMENTS:

This study was supported by Yeditepe University. All data and figures used in this article were previously published<sup>34</sup>.

#### DISCLOSURES:

The authors have nothing to disclose.

#### REFERENCES

- 1 Camberlain, G., Fox, J., Ashton, B., Middleton, J. Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells*. **25** (11), 2739-2749 (2007).
- 2 Demirci, S., Doğan, A., Şahin, F. in *Dental Stem Cells*. 109-124 (Springer, 2016).
- 3 Fox, J. M., Chamberlain, G., Ashton, B. A., Middleton, J. Recent advances into the understanding of mesenchymal stem cell trafficking. *British journal of haematology*. **137** (6), 491-502 (2007).
- 4 Chang, A. I., Schwertschkow, A. H., Nolta, J. A., Wu, J. Involvement of mesenchymal stem cells in cancer progression and metastases. *Current cancer drug targets*. **15** (2), 88-98 (2015).
- 5 Dvorak, H. F. Tumors: wounds that do not heal. *New England Journal of Medicine*. **315** (26), 1650-1659 (1986).
- 6 Lu, Y.-r. *et al.* The growth inhibitory effect of mesenchymal stem cells on tumor cells *in vitro* and *in vivo*. *Cancer biology & therapy*. **7** (2), 245-251 (2008).
- 7 Secchiero, P. *et al.* Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. *PloS one*. **5** (6), e11140 (2010).
- 8 Hong, I.-S., Lee, H.-Y., Kang, K.-S. Mesenchymal stem cells and cancer: friends or enemies? *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*. **768** 98-106 (2014).
- 9 Brennen, W. N., Chen, S., Denmeade, S. R., Isaacs, J. T. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. *Oncotarget*. **4** (1), 106 (2013).
- 10 Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., Marini III, F. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? *Stem cells*. **29** (1), 11-19 (2011).
- 11 Albini, A., Sporn, M. B. The tumour microenvironment as a target for chemoprevention. *Nature Reviews Cancer*. **7** (2), 139 (2007).

482 12 Quante, M. *et al.* Bone marrow-derived myofibroblasts contribute to the mesenchymal  
483 stem cell niche and promote tumor growth. *Cancer cell*. **19** (2), 257-272 (2011).

484 13 Gronthos, S., Mankani, M., Brahimi, J., Robey, P. G., Shi, S. Postnatal human dental pulp  
485 stem cells (DPSCs) *in vitro* and *in vivo*. *Proceedings of the National Academy of Sciences*. **97** (25),  
486 13625-13630 (2000).

487 14 Mori, G. *et al.* Dental pulp stem cells: osteogenic differentiation and gene expression.  
488 *Annals of the New York Academy of Sciences*. **1237** (1), 47-52 (2011).

489 15 Mori, G. *et al.* Osteogenic properties of human dental pulp stem cells. *Journal of biological*  
490 *regulators and homeostatic agents*. **24** (2), 167-175 (2010).

491 16 Kerkis, I. *et al.* Isolation and characterization of a population of immature dental pulp stem  
492 cells expressing OCT-4 and other embryonic stem cell markers. *Cells Tissues Organs*. **184** (3-4),  
493 105-116 (2006).

494 17 Potdar, P. D., Jethmalani, Y. D. Human dental pulp stem cells: applications in future  
495 regenerative medicine. *World journal of stem cells*. **7** (5), 839 (2015).

496 18 Ahmed, N. E.-M. B., Murakami, M., Hirose, Y., Nakashima, M. Therapeutic potential of  
497 dental pulp stem cell secretome for Alzheimer's disease treatment: an *in vitro* study. *Stem cells*  
498 *international*. **2016** (2016).

499 19 Gorin, C. *et al.* Priming dental pulp stem cells with fibroblast growth factor-2 increases  
500 angiogenesis of implanted tissue-engineered constructs through hepatocyte growth factor and  
501 vascular endothelial growth factor secretion. *Stem cells translational medicine*. **5** (3), 392-404  
502 (2016).

503 20 Wakayama, H. *et al.* Factors secreted from dental pulp stem cells show multifaceted  
504 benefits for treating acute lung injury in mice. *Cytotherapy*. **17** (8), 1119-1129 (2015).

505 21 Doğan, A. *et al.* Differentiation of human stem cells is promoted by amphiphilic pluronic  
506 block copolymers. *International Journal of Nanomedicine*. **7** 4849 (2012).

507 22 Taşlı, P. N., Doğan, A., Demirci, S., Şahin, F. Boron enhances odontogenic and osteogenic  
508 differentiation of human tooth germ stem cells (hTGSCs) *in vitro*. *Biological trace element*  
509 *research*. **153** (1-3), 419-427 (2013).

510 23 Yalvac, M. *et al.* Isolation and characterization of stem cells derived from human third  
511 molar tooth germs of young adults: implications in neo-vascularization, osteo-, adipo- and  
512 neurogenesis. *The pharmacogenomics journal*. **10** (2), 105 (2010).

513 24 Doğan, A. *et al.* Sodium pentaborate pentahydrate and pluronic containing hydrogel  
514 increases cutaneous wound healing *in vitro* and *in vivo*. *Biological trace element research*. **162** (1-  
515 3), 72-79 (2014).

516 25 Doğan, A., Yalvaç, M. E., Yılmaz, A., Rizvanov, A., Şahin, F. Effect of F68 on  
517 cryopreservation of mesenchymal stem cells derived from human tooth germ. *Applied*  
518 *biochemistry and biotechnology*. **171** (7), 1819-1831 (2013).




519 26 Rizvanov, A. A. *et al.* Interaction and self-organization of human mesenchymal stem cells  
520 and neuro-blastoma SH-SY5Y cells under co-culture conditions: A novel system for modeling  
521 cancer cell micro-environment. *European Journal of Pharmaceutics and Biopharmaceutics*. **76** (2),  
522 253-259 (2010).

523 27 Troiano, L. *et al.* Multiparametric analysis of cells with different mitochondrial membrane  
524 potential during apoptosis by polychromatic flow cytometry. *Nature protocols*. **2** (11), 2719  
525 (2007).


- 28 Melzer, C., von der Ohe, J., Lehnert, H., Ungefroren, H., Hass, R. Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells. *Molecular cancer*. **16** (1), 28 (2017).
- 29 Aguirre, A., Planell, J., Engel, E. Dynamics of bone marrow-derived endothelial progenitor cell/mesenchymal stem cell interaction in co-culture and its implications in angiogenesis. *Biochemical and biophysical research communications*. **400** (2), 284-291 (2010).
- 30 Bogdanowicz, D. R., Lu, H. H. in *Biomimetics and Stem Cells*. 29-36 (Springer, 2013).
- 31 Plotnikov, E. *et al.* Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture. *Journal of cellular and molecular medicine*. **12** (5a), 1622-1631 (2008).
- 32 Bogdanowicz, D. R., Lu, H. H. Studying cell-cell communication in co-culture. *Biotechnology journal*. **8** (4), 395-396 (2013).
- 33 Brunetti, G. *et al.* High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability. *Oncology reports*. **39** (4), 2031-2039 (2018).
- 34 Doğan, A., Demirci, S., Apdik, H., Apdik, E. A., Şahin, F. Dental pulp stem cells (DPSCs) increase prostate cancer cell proliferation and migration under *in vitro* conditions. *Tissue and Cell*. **49** (6), 711-718 (2017).



Figure 1

[Click here to access/download;Figure;Figure 1.pdf](#)









Name	Company	Catalog number/Model	Comments
DMEM	Invitrogen	11885084	For cell culture
FBS	Invitrogen	16000044	For cell culture
PSA	Lonza	17-745E	For cell culture
Trypsin	Invitrogen	25200056	For cell dissociation
PBS	Invitrogen	10010023	For washes
Dexamethasone	Sigma	D4902	Component of differentiation media
$\beta$ -Glycerophosphate	Sigma	G9422	Component of osteogenic differentiation medium
Ascorbic acid	Sigma	A4544	Component of osteo- and chondro-genic differentiation medium
Insulin-Transferrin-Selenium (ITS –G)	Invitrogen	41400045	Component of chondrogenic differentiation medium
TGF- $\beta$	Sigma	SRP3171	Component of chondrogenic differentiation medium
Insulin	Sigma	I6634	Component of adipogenic differentiation medium
Isobutyl-1-methylxanthine (IBMX)	Sigma	I7018	Component of adipogenic differentiation medium
Indomethacin	Sigma	I7378	Component of adipogenic differentiation medium
MTS Reagent	Promega	G3582	Cell viability analyses
TUNEL Assay	Sigma	11684795910	Apoptotic analyses
24-well plate inserts	Corning	3396	For trans-well migration assay

PKH67	Sigma	PKH67GL	For co-culture cell staining
PKH26	Sigma	PKH26GL	For co-culture cell staining
Paraformaldehyde	Sigma	P6148	For cell fixation
von Kossa Kit	BioOptica	04-170801.A	For cell staining (differentiation)
Alcian blue	Sigma	A2899	For cell staining (differentiation)





1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Mesenchymal stem cells (MSC) isolation from pulp tissue,  
co-culture with cancer cells and their interactions

Author(s):

Aysegül Doğan, Selami Demirci, Hüseyin Apçelik, Ezgi Ayşar Apçelik,  
Fikretin Şahin

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

## ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole



## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

**12. Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

**13. Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

**14. Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:

Selami Demirci

Department:

Sickle Cell Branch / NHLBI


Institution:

National Institutes of Health (NIH)

Title:

PhD

Signature:



Date:

07/25/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

This piece of the submission is being sent via mail.



9/4/2018

**The editor of JoVE Journal,**

**RESPONSE TO REVIEWERS**

**Title of Manuscript:** Mesenchymal Stem Cell Isolation from Pulp Tissue and Co-Culture with Cancer Cells to Study Their Interactions

**Corresponding author's name:** Selami Demirci

**Current Address:**

Sickle Cell Branch,

National Heart, Lung, and Blood Institute, Bethesda, Maryland.

[selami.demirci@nih.gov](mailto:selami.demirci@nih.gov), [selamidemirci@hotmail.com](mailto:selamidemirci@hotmail.com)

In accordance with the reviewers' suggestions, necessary explanations and clarifications were added to the revised manuscript. Please find detailed response to reviewers' suggestions below.

## **Revision Letter**

1. The title has been rephrased. Please feel free to change if the authors do not agree with this change.

**Response:** Authors agreed with the rephrased title

2. Because human teeth have been used in this protocol, please include an ethics statement before the numbered protocol steps, indicating that the protocol follows the guidelines of your institution's **human research** ethics committee.

**Response:** Required statement was included as a note to the protocol part 1.1

**Note:** Written informed consent of the patients was obtained after the approval from the Institutional Ethics Committee. “

3. Does it refer to complete DMEM medium with 10% FBS and 1% PSA mentioned in line 91? “complete DMEM medium” and “DMEM supplemented with 10% FBS and 1% PSA” appear in multiple places. It is not clear whether they refer to the same thing. Please clarify throughout the manuscript.

**Response:** These two statements refer to same medium formulation. Statement in line 91 was clarified and “complete DMEM” statement was used throughout the manuscript (line 106, 113,120,124,144,166,188,206,228,238,244,256,284,295).

4. These two steps have been reorganized. Please check for accuracy. Please add more details to step 1.7.

**Response:** Authors agreed with the reorganized parts and step 1.7 was detailed.

5. From step 1.6? Please specify.

**Response:** Required statement was added.

6. Please specify from which step the cells are obtained.

**Response:** Required statement was added.

7. Please specify the concentration/volume of antibodies used, if applicable.

**Response:** Concentration and volume of the antibodies were added to 2.2.4

8. Please describe how flow cytometry analysis is done.

**Response:** Required explanation was added as a note to 2.2.5

9. Does it refer to complete DMEM medium with 10% FBS and 1% PSA mentioned in line 91?

**Response:** Yes it refers to same medium formulation in line 91. Required explanation was added.

10. Although a reference has been provided, more details about how to actually perform these analyses are needed for filming. Please consider un-highlighting this step.

**Response:** These analyses are not the main experiments for this manuscript. Therefore, we included von Kossa and Alcian blue staining as note to the part 2.3.4. von Kossa and Alcian blue were added to the table of materials. Because von Kossa and Alcian blue stainings might be visually suitable for filming, we preferred to include.

11. What media? And from which step? Please specify.

**Response:** Required statement was added.

12. We generally require software steps to be more explicitly explained ('click', 'select', etc.). Please add such details.

**Response:** Software steps were detailed as note in step 4.4.4

13. Should this be flow cytometry analysis?

**Response:** The heading of step 6 was changed.

14. Although a reference has been provided, more details about how to actually label the cells are needed for filming. Otherwise we can not film this step.

**Response:** Steps of 6.1 to 6.4 explain the staining process according to the manufacturer's instructions

15. Please include the information of the commercial kit in the Table of Materials.

**Response:** PKH67 and PKH26 staining kits have already been included to the table of materials.

16. Do you have any funding sources supporting this work? If so, they should be mentioned in this section.

**Response:** This study was supported by Yeditepe University and required statement was added to the Acknowledgements part.